Healthcare / BiotechnologyNasdaqCM
$0.41
-0.07 (-14.98%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-8.3M · quality 55.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
24/100
D
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$10M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-3992.2%
↓Gross Margin
93.4%
↑Debt/Equity
N/A
•TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2009–2025 · 16 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
-3031.7%
FCF / Net income
0.77x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $359700.0 · net income $-14.2M · FCF $-10.9M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||||||||||
| Revenue | $359700.00 | $359700.00 | $401000.00 | $145800.00 | $119800.00 | $46000.00 | $77000.00 | $130000.00 | $111000.00 | $81000.00 | $36355.00 | $628915.00 | $415996.00 | $1680.00 | $15589.00 | $0.00 | — | — |
| Net Income | $-14.2M | $-14.2M | $-9.0M | $-10.4M | $-13.2M | $-44.3M | $-11.3M | $-14.6M | $-12.5M | $-9.4M | $-8.6M | $-7.9M | $-5.6M | $-5.8M | $-6.5M | $-4.1M | $-2.3M | $-1.2M |
| EBITDA | $-15.4M | $-15.4M | $-11.4M | $-15.0M | $-18.7M | $-26.2M | $-2.6M | $-8.2M | $-7.4M | $-8.1M | $-7.5M | $-7.0M | $-4.8M | $-4.6M | $-5.5M | $-3.5M | $-2.0M | — |
| EPS | -1.58 | -1.58 | -1.16 | -2.47 | -3.65 | -37.30 | — | — | — | — | — | — | — | — | — | — | — | — |
| Gross Margin | 93.4% | 93.4% | 93.0% | 100.0% | — | — | — | — | — | 100.0% | 99.7% | 58.4% | 48.6% | 87.6% | 91.6% | — | — | — |
| Operating Margin | -4350.1% | -4350.1% | -2881.6% | -10382.3% | -15745.8% | -57191.0% | -3574.1% | -6486.2% | -6889.8% | -10338.6% | -21414.0% | -1140.1% | -1183.3% | -282873.2% | -35746.1% | — | — | — |
| Net Margin | -3959.4% | -3959.4% | -2239.2% | -7145.2% | -11037.0% | -96311.5% | -14639.9% | -11267.6% | -11277.3% | -11660.1% | -23755.4% | -1259.9% | -1343.2% | -342333.0% | -41931.6% | — | — | — |
| Balance Sheet | ||||||||||||||||||
| Debt/Equity | — | — | — | 0.02 | 0.03 | 0.02 | — | — | — | — | — | — | — | — | — | — | -0.26 | — |
| Current Ratio | 0.84 | 0.84 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Cash Flow | ||||||||||||||||||
| Free Cash Flow | $-10.9M | $-10.9M | $-8.3M | $-6.6M | $-6.4M | $-3.4M | — | $-7.0M | $-5.1M | $-3.9M | — | — | — | $-9.6M | $-3.2M | $-2.8M | $-774601.00 | — |
| Returns | ||||||||||||||||||
| ROE | -3992.2% | -3992.2% | -105.3% | -104.1% | -128.5% | -410.9% | 846.6% | 114.7% | 144.9% | 138.1% | 172.7% | 202.7% | 81.1% | 86.0% | 127.1% | 110.5% | 304.2% | 2343.3% |
| Valuation | ||||||||||||||||||
| P/B | 10.24 | 10.24 | 1.37 | 0.71 | 1.07 | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Growth & Yield | ||||||||||||||||||
| Revenue Growth | -10.3% | -10.3% | 175.0% | 21.7% | — | -40.3% | -40.8% | 17.1% | 37.0% | 122.8% | -94.2% | 51.2% | 24661.7% | -89.2% | — | — | — | — |
| EPS Growth | -36.2% | -36.2% | 53.0% | 32.3% | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-76.8%
Start / end P/E
n/dx → n/dx
EPS bridge
-1.16 → -1.58
Residual
-76.8%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.